Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I

NeuroImage

Volumn 9, Issue 1, 1999, Pages 108-116

  Hall, H ^a   Halldin, C ^a   Guilloteau, D ^b   Chalon, S ^b   Emond, P ^b   Besnard, J C ^b   Farde, L ^a   Sedvall, G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b INSERM   (France)

Author keywords

Dopamine transporter; Human brain; Whole hemisphere autoradiography; 125I PE2I

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CITALOPRAM; DOPAMINE TRANSPORTER; IODINE 125; MAPROTILINE; NORTROPANE DERIVATIVE; VANOXERINE;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN RADIOGRAPHY; CADAVER; CAUDATE NUCLEUS; CEREBELLUM; FEMALE; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIPOPHILICITY; MALE; NEOCORTEX; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PUTAMEN; SUBSTANTIA NIGRA; WHITE MATTER;

EID: 0032799203     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1006/nimg.1998.0366     Document Type: Article

References (48)

1. Alburges M. E., Narang N., Wamsley J. K. Alterations in the dopaminergic receptor system after chronic administration of cocaine. Synapse. 14:1993;314-323.
2. Allard P. O., Rinne J., Marcusson J. O. Dopamine uptake sites in Parkinsons disease and dementia of the Alzheimer type. Brain Res. 637:1994;262-266.
3. 33. J. Neural Transm. 97:1994;27-40.
4. 123. Nucl. Med. Biol. 22:1995;211-219.
5. Bannon M. J., Granneman J. G., Kapatos G. The dopamine transporter: potential involvement in neuropsychiatric disorders. Psychopharmacology: The Fourth Generation of Progress. 1995;Raven Press, New York. p. 179-188.
6. Bannon M. J., Poosch M. S., Xia Y., Goebel D. J., Cassin B., Kapatos G. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc. Natl. Acad. Sci. USA. 89:1992;7095-7099.
7. 125. Mol. Pharmacol. 47:1995;779-786.
8. Boja J. W., Vaughan R., Patel A., Shaya E. K., Kuhar M. J. The dopamine transporter. Niznik H. B. Dopamine Receptors. 1994;611-644 Marcel Dekker, New York.
9. 3. Brain Res. 486:1989;261-268.
10. 33. Synapse. 6:1990;189-195.
11. Chalon S., Emond P., Garreau L., Frangin Y., Mauclaire L., Guilloteau D., Besnard J. C. Characterization of the cocaine derivative PE2I, a high specific marker for imaging the dopamine transporter by SPECT. Eur. J. Nucl. Med. 24:1997a;880.
12. Chalon S., Emond P., Thiercelin C., Bodard S., Garreau L., Frangin Y., Mauclaire L., Besnard J.-C., Guilloteau D. N. J. Nucl. Med. 38:1997b;76P.
13. Ciliax B. J., Heilman C., Demchyshyn L. L., Pristupa Z. B., Ince E., Hersch S. M., Niznik H. B., Levey A. I. The dopamine transporter: Immunochemical characterization and localization in brain. J. Neurosci. 15:1995;1714-1723.
14. Coyle J. T., Snyder S. H. Catecholamine uptake by synaptosomes in homogenates of rat brain: Stereospecificity in different areas. J. Pharmacol. Exp. Ther. 170:1969;221-231.
15. Emond P., Garreau L., Chalon S., Boazi M., Caillet M., Bricard J., Frangin Y., Mauclaire L., Besnard J.-C., Guilloteau D. Synthesis and ligand binding of nortropane derivatives:NN. J. Med. Chem. 40:1997;1366-1372.
16. 11. Synapse. 16:1994;93-103.
17. Ginovart N., Lundin A., Farde L., Halldin C., Bäckman L., Swahn C.-G., Pauli S., Sedvall G. PET study of the pre- and postsynaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain. 120:1997;501-516.
18. Giros B., Elmestikawy S., Bertrand L., Caron M. G. Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett. 295:1991;149-154.
19. Graybiel A. M., Moratalla R. Dopamine uptake sites in the striatum are distributed differentially in striosome and matrix compartments. Proc. Natl. Acad. Sci. USA. 86:1989;9020-9024.
20. 125125125. Nucl. Med. Biol. 24:1997;629-634.
21. 125. Synapse. 23:1996;115-123.
22. 33. J. Neural Transm. 73:1988;7-21.
23. Hall H., Halldin C., Guilloteau D., Lundkvist C., Chalon S., Emond P., Besnard J. C., Farde L., Sedvall G. Dopamine transporters in the post-mortem human brain. Autoradiographic localisation using [I-125]PE2I. Eur. J. Nucl. Med. 24:1997;880.
24. 12. Neuropsychopharmacology. 11:1994;245-256.
25. 11. Synapse. 22:1996;386-390.
26. Halldin C., Lundkvist C., Guilloteau D., Olsson H., Karlsson P., Hall H., Chalon S., Emond P., Swahn C.-G., Farde L. The first selective dopamine transporter radioligand suitable for quantitation with both PET and SPECT. Eur. J. Nucl. Med. 24:1997;1057.
27. 3. Jpn. J. Pharmacol. 47:1988;237-243.
28. 2. Neuroscience. 63:1994;357-362.
29. 123. Eur. J. Pharmacol. 200:1991;369-370.
30. Innis R. B., Seibyl J. P., Scanley B. E., Laruelle M., Abi-Dargham A., Wallace E., Baldwin R. M., Zea-Ponce Y., Zoghbi S., Wang S., Gao Y., Neumeyer J. L., Charney D. S., Hoffer P. B., Marek K. L. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc. Natl. Acad. Sci. USA. 90:1993;11965-11969.
31. Iversen L. L., Snyder S. H. Synaptosomes: different populations storing catecholamines and gamma-aminobutyric acid in homogenates of rat brain. Nature. 220:1968;796-798.
32. 125. J. Pharmacol. Exp. Ther. 274:1995;1473-1483.
33. Lundkvist C., Halldin C., Guilloteau D., Olsson H., Karlsson P., Chalon S., Emond P., Frangin Y., Hall H., Swahn C.-G., Farde L. Development of a selective radioligand for quantitation of the dopamine transporter with both PET and SPECT. J. Labelled Comp. Radiopharm. 40:1997;580-582.
34. 11. Nucl. Med. Biol. 22:1995;905-913.
35. Meister B., Elde R. Dopamine transporter mRNA in neurons of the rat hypothalamus. Neuroendocrinology. 58:1993;388-395.
36. 123. J. Med. Chem. 34:1991;3144-3146.
37. Neumeyer J. L., Wang S. Y., Gao Y. G., Milius R. A., Kula N. S., Campbell A., Baldessarini R. J., Zea-Ponce Y., Baldwin R. M., Innis R. B. N-ω-fluoroalkyl analogs of (1R)-2-β-carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): Radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J. Med. Chem. 37:1994;1558-1561.
38. 11. J. Neurosci. Methods. 36:1991;53-61.
39. Rekker R. F., Mannhold R. Calculation of Drug Lipophilicity. The Hydrophobic Fragmental Constant Approach. 1992;VCH, New York.
40. Revay R., Vaughan R., Grant S., Kuhar M. J. Dopamine transporter immunohistochemistry in median eminence, amygdala, and other areas of the rat brain. Synapse. 22:1996;93-99.
41. 123/125in vivo. Synapse. 11:1992;134-139.
42. Seeman P., Niznik H. B. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J. 4:1990;2737-2744.
43. Shimada S., Kitayama S., Walther D., Uhl G. Dopamine transporter mRNA: Dense expression in ventral midbrain neurons. Mol. Brain Res. 13:1992;359-362.
44. Singer H. S., Hahn I. H., Moran T. H. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann. Neurol. 30:1991;558-562.
45. 125In vitro. J. Neurochem. 62:1994;549-556.
46. 3125. J. Labelled Comp. Radiopharm. 38:1996;675-685.
47. 3. J. Pharmacol. Exp. Ther. 260:1992;427-436.
48. Zelnik N., Angel I., Paul S. M., Kleinman J. E. Decreased density of human striatal dopamine uptake sites with age. Eur. J. Pharmacol. 126:1986;175-176.